Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:0070780 |
| Name | hormone receptor-positive/HER2-negative breast cancer |
| Definition | A HER2 negative breast cancer characterized by at least one of the estrogen or progesterone receptors and the absence of HER2 (EBBR2) protein. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Xrefs |
|
| Path | disease disease of cellular proliferation cancer organ system cancer breast cancer HER2 negative breast cancer hormone receptor-positive/HER2-negative breast cancer |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04557449 | Phase Ib/II | Letrozole + PF-07220060 Fulvestrant + PF-07220060 PF-07220060 + Tamoxifen Giredestrant + PF-07220060 Enzalutamide + PF-07220060 PF-07220060 Midazolam + PF-07220060 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i) | Recruiting | USA | SVK | GBR | CZE | ARG | 3 |
| NCT07748208 | Phase II | Fulvestrant + Inavolisib + Palbociclib | A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes | Recruiting | USA | 1 |